ArticleBMC medical imaging2026
Comparison of CT-based radiomics models for the prediction of human epidermal growth factor receptor 2 status in gastric cancer.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAccurate prediction of human epidermal growth factor receptor 2 (HER2) status is critical for personalized treatment strategies in gastric cancer (GC). This study aimed to develop and validate HER2 status prediction models integrating clinical and radiomics features to enhance predictive accuracy.
methodsWe retrospectively analyzed data from GC patients to identify independent predictors of HER2 status using multivariate logistic regression (LR). A radiomics model was constructed using five machine learning classifiers, with feature selection and Rad-score calculation. The combined model incorporated clinical predictors and Rad-score via LR. Model performance was evaluated using the area under the curve (AUC), calibration curves, and decision curve analysis (DCA).
resultsPathological T stage, pathologic N stage, and CEA levels were identified as independent predictors of HER2 status (all p < 0.05). The support vector machine (SVM)-based radiomics model achieved the highest AUC (0.823) in the testing set. The combined model demonstrated superior predictive performance in both the training (AUC = 0.889) and testing (AUC = 0.826) cohorts compared to clinical model alone.
conclusionsThe integration of CT-based radiomics with clinical factors significantly improved the prediction of HER2 status in GC, outperforming models based on either data type alone.
trial registrationNot applicable (retrospective study).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.